Advanced development and validation of targeted molecular counting methods for precise and ultrasensitive quantitation of low prevalence somatic mutations
先进的开发和验证靶向分子计数方法,用于低流行体细胞突变的精确和超灵敏定量
基本信息
- 批准号:9061644
- 负责人:
- 金额:$ 37.59万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-05-01 至 2018-04-30
- 项目状态:已结题
- 来源:
- 关键词:Acute Myelocytic LeukemiaAddressAdvanced DevelopmentAllelesBasic ScienceBiological AssayBiological MarkersBlood CirculationCLIA certifiedCancer DetectionCancer DiagnosticsCancer PatientCatalogingCatalogsCell LineCellsCharacteristicsClinicalConsensusDNA SequenceDetectionDetection of Minimal Residual DiseaseDiagnosisDiagnosticDiseaseDrug resistanceEarly DiagnosisEventExonsFlow CytometryFrequenciesGene FrequencyGenesGenetic screening methodGoalsGoldHaploidyHealthHereditary DiseaseIndividualLaboratoriesLow PrevalenceMalignant NeoplasmsMassive Parallel SequencingMeasurementMeasuresMediatingMethodologyMethodsMindMolecularMolecular AnalysisMolecular TargetMonitorMonitoring for RecurrenceMutateMutationNon-Invasive Cancer DetectionOutcomePatient CarePatientsPerformancePrognostic MarkerPropertyReactionReadingReagentRecurrenceRecurrent diseaseRelapseReproducibilityResidual NeoplasmResidual stateSamplingScreening for cancerSiteSomatic MutationSpecificitySpecimenTechnologyTimeValidationactionable mutationanticancer researchbasecancer genomecancer recurrencecancer therapycell free DNAclinical applicationclinical practiceclinically relevantcombinatorialcostcost effectivecost effectivenessdesigndiagnostic assayexome sequencinggenome sequencinggenomic biomarkerinsertion/deletion mutationmeetingsmultiplex detectionmutantneoplastic cellnoveloutcome forecastpersonalized medicineprogenitorprognosticresearch clinical testingresistance mutationtargeted sequencingtechnology validationtooltumortumor DNAwhole genome
项目摘要
DESCRIPTION (provided by applicant): The ultrasensitive detection of clinically relevant somatic alterations in cancer genomes has great potential for impacting patient care, e.g. for early detection, establishing diagnoses, refining prognoses, guiding treatment, and monitoring recurrence. However, current technologies are poorly suited to the robust detection of somatic mutations present at very low frequencies (<1%). Massively parallel sequencing represents an advantageous path forward, but its sensitivity to detect very rare events is fundamentally constrained by the sequencing error rate. We have recently developed a new experimental paradigm that overcomes this limitation. In our approach, each copy of a target sequence that is present in a sample is molecularly tagged during the first cycle of a multiplex capture reaction with a unique random sequence. After amplification, target amplicons and their corresponding molecular tags are subjected to massively parallel sequencing. During analysis, the molecular tags are used to associate sequence reads sharing a common origin. Through oversampling, reads bearing the same molecular tag error-correct one another to yield an independent haploid consensus for each progenitor molecule. Furthermore, the collapsing of commonly derived reads inherently corrects for any allele-specific bias during amplification, such that estimates of
mutant allele frequency can be accompanied by precise confidence bounds ("molecular counting"). Among other benefits, the approach is sensitive to at least 1 mutated sequence in a background of 10,000 unmutated copies. Here we propose the advanced development and validation of this approach for use as a clinical diagnostic. In our first aim, we will develop a multiplexed panel to broadly target common cancer associated mutations using this technology. In our second aim, we will apply the panel to the detection of minimal residual disease in acute myeloid leukemia as a prognostic marker of disease relapse. In our third aim, we will apply the panel to detection of ultra-rare mutations in circulating cell-free DNA, which is released into circulation from dying tumor cells, as a robust and non-invasive cancer diagnostic. The panel will be rigorously validated for clinical use in both aims, with performance metrics appropriately designed for the two separate analytes. The availability of robust, cost-effective, quantitative, and generically applicable tools for the ultrasensitive, multiplex detection of rare somatic events
in the clinical setting will provide enhanced, transformative capabilities in the diagnosis and monitoring of cancers. The methodology will also have application to basic science cancer research.
描述(由申请人提供):对癌症基因组中临床相关的体细胞变化的超灵敏检测在影响患者护理方面具有巨大的潜力,例如,在早期发现、确定诊断、改善预后、指导治疗和监测复发方面。然而,目前的技术不太适合对存在于极低频率(<;1%)的体细胞突变进行稳健的检测。大规模并行测序代表着一条有利的前进道路,但其检测非常罕见的事件的灵敏度从根本上受到测序错误率的限制。我们最近开发了一种新的实验范式,克服了这一限制。在我们的方法中,存在于样本中的靶序列的每个拷贝在与唯一随机序列的多重捕获反应的第一个周期中被分子标记。扩增后,对靶扩增产物及其相应的分子标签进行大规模平行测序。在分析过程中,分子标签被用来关联共享共同起源的序列读数。通过过度采样,带有相同分子标签的读数相互纠错,为每个前体分子产生独立的单倍体共识。此外,共同派生的读数的折叠本质上纠正了扩增过程中任何等位基因特定的偏见,这样估计
突变等位基因频率可以伴随着精确的置信限(“分子计数”)。除其他优点外,该方法对10,000个未突变拷贝的背景中至少1个突变序列敏感。在这里,我们建议进一步开发和验证这一方法,以用于临床诊断。在我们的第一个目标中,我们将开发一个多路小组,使用这项技术来广泛地针对常见的癌症相关突变。在我们的第二个目标中,我们将该小组应用于检测急性髓系白血病的微小残留病,作为疾病复发的预后标志。在我们的第三个目标中,我们将应用该小组来检测循环中无细胞DNA的超罕见突变,作为一种强大的非侵入性癌症诊断方法,该DNA从濒死的肿瘤细胞释放到循环中。该小组将在两个目标的临床使用中进行严格的验证,并为两个单独的分析物设计适当的性能指标。用于罕见躯体事件的超灵敏、多重检测的可靠、经济、定量和普遍适用的工具的可用性
在临床环境中,将在癌症诊断和监测方面提供增强的、变革性的能力。该方法也将应用于基础科学癌症研究。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Stephen J Salipante其他文献
Stephen J Salipante的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Stephen J Salipante', 18)}}的其他基金
Efficient, cost-effective, and ultrasensitive sequencing of somatic mutations
高效、经济且超灵敏的体细胞突变测序
- 批准号:
10488391 - 财政年份:2022
- 资助金额:
$ 37.59万 - 项目类别:
Efficient, cost-effective, and ultrasensitive sequencing of somatic mutations
高效、经济且超灵敏的体细胞突变测序
- 批准号:
10675690 - 财政年份:2022
- 资助金额:
$ 37.59万 - 项目类别:
Advanced sequencing methods for repeat expansion disorders: exploring the dark matter of next-generation sequencing
重复扩增障碍的先进测序方法:探索下一代测序的暗物质
- 批准号:
9360220 - 财政年份:2017
- 资助金额:
$ 37.59万 - 项目类别:
Advanced development and validation of targeted molecular counting methods for precise and ultrasensitive quantitation of low prevalence somatic mutations
先进的开发和验证靶向分子计数方法,用于低流行体细胞突变的精确和超灵敏定量
- 批准号:
9269176 - 财政年份:2015
- 资助金额:
$ 37.59万 - 项目类别:
Advanced development and validation of targeted molecular counting methods for precise and ultrasensitive quantitation of low prevalence somatic mutations
先进的开发和验证靶向分子计数方法,用于低流行体细胞突变的精确和超灵敏定量
- 批准号:
9515203 - 财政年份:2015
- 资助金额:
$ 37.59万 - 项目类别:
Advanced development and validation of targeted molecular counting methods for precise and ultrasensitive quantitation of low prevalence somatic mutations
先进的开发和验证靶向分子计数方法,用于低流行体细胞突变的精确和超灵敏定量
- 批准号:
8849721 - 财政年份:2015
- 资助金额:
$ 37.59万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 37.59万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 37.59万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 37.59万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 37.59万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 37.59万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 37.59万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 37.59万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 37.59万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 37.59万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 37.59万 - 项目类别:
Research Grant